Zie ook in gerelateerde artikelen voor meer artikelen over immuuntherapie bij blaaskanker en urineleiderkanker

10 december 2021: Uit de vervolgstudie op dCHECKMATE274 fase III studie blijkt bij patiënten met hoog-risico spierinvasief urotheelcarcinoom (MIUC) (blaaskanker) die een volledige operatie hadden ondergaan en bij patiënten met een PD-L1-expressieniveau van ≥1%, aanvullende immuuntherapie met nivolumab de ziektevrije overleving te verbeteren. De mediane ziektevrije tijd in de intention-to-treat (ITT)-populatie was 20,8 maanden met nivolumab en 10,8 maanden met placebo. Deze gegevens veranderen de praktijk en leidden tot de goedkeuring door de Amerikaanse FDA van adjuvans nivolumab op 20 augustus 2021 bij patiënten met urotheelcarcinoom die een hoog risico lopen op een recidief na radicale resectie, ongeacht eerdere behandeling met neoadjuvante chemotherapie, betrokkenheid van de nodale of PD-L1-status.

Alle cijfers en details zijn te lezen in dit studieverslag gepubliceerd 2 december 2021, zie ook referenties onderaan dit artikel: 

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma





9 februari 2017: The Lancet 7 februari 20 17

Nivolumab, een anti-PD medicijn, gegeven aan patienten met gevorderde blaaskanker (urineleiderkanker) na resistentie van op platinum gebaseerde chemo zorgt alsnog voor uitstekende resultaten op progressievrije ziekte en verlenging van overall overleving. Zelfs bij patienten met weinig PD1 ligand expressie hadden voordeel van de nivolumab. 

Nivolumab gaf een mediane remissie / respons te zien bij 19.6% van de patiënten (N = 270) met uitgezaaide blaaskanker na minstens 1 op platina gebaseerde chemokuur, inclusief 28.4%, 23.8%, en 16.1% respectievelijk bij degenen met een PD-L1 expressie van ≥ 5%, ≥ 1%, en < 1%, respectievelijk. De uiteindelijke resutlaten zullen nog beter worden want de mediane repons is nog niet bereikt op moment van analyse. Maar dat 1 op de 5 patienten alsnog een remissie bereikt is wel goed natuurlijk.

De FDA geeft op basis van deze studieresultaten uit de fase II CheckMate 275 studie ook officieel toestemming voor gebruik van nivolumab als immuuntherapie bij deze patiëntengroep. De studie werd gepubliceeerd in The Lancet Oncology

nivolumab bij blaaskanker

Voor het volledige studierapport: Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial moet betaald worden

Hieronder het abstract van de studie:

Nivolumab monotherapy provided meaningful clinical benefit, irrespective of PD-L1 expression, and was associated with an acceptable safety profile in previously treated patients with metastatic or surgically unresectable urothelial carcinoma.

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

Prof Padmanee Sharma, MD'Correspondence information about the author Prof Padmanee Sharma
,
Prof Margitta Retz, MD
,
Arlene Siefker-Radtke, MD
,
Ari Baron, MD
,
Andrea Necchi, MD
,
Prof Jens Bedke, MD
,
Elizabeth R Plimack, MD
,
Daniel Vaena, MD
,
Prof Marc-Oliver Grimm, MD
,
Sergio Bracarda, MD
,
José Ángel Arranz, MD
,
Sumanta Pal, MD
,
Prof Chikara Ohyama, MD
,
Abdel Saci, PhD
,
Xiaotao Qu, PhD
,
Alexandre Lambert, PhD
,
Suba Krishnan, MD
,
Alex Azrilevich, PharmD
,
Prof Matthew D Galsky, MD
Dr Qu is now an employee of Johnson and Johnson, Pennington, NJ, USA


Summary

Background

Patients with metastatic urothelial carcinoma have a dismal prognosis and few treatment options after first-line chemotherapy. Responses to second-line treatment are uncommon. We assessed nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, for safety and activity in patients with metastatic or surgically unresectable urothelial carcinoma whose disease progressed or recurred despite previous treatment with at least one platinum-based chemotherapy regimen.

Methods

In this multicentre, phase 2, single-arm study, patients aged 18 years or older with metastatic or surgically unresectable locally advanced urothelial carcinoma, measurable disease (according to Response Evaluation Criteria In Solid Tumors v1.1), Eastern Cooperative Oncology Group performance statuses of 0 or 1, and available tumour samples for biomarker analysis received nivolumab 3 mg/kg intravenously every 2 weeks until disease progression and clinical deterioration, unacceptable toxicity, or other protocol-defined reasons. The primary endpoint was overall objective response confirmed by blinded independent review committee in all treated patients and by tumour PD-L1 expression (≥5% and ≥1%). This trial is registered with ClinicalTrials.gov, number NCT02387996, and is completed. Follow-up is still ongoing.

Findings

Between March 9, 2015, and Oct 16, 2015, 270 patients from 63 sites in 11 countries received nivolumab, and 265 were evaluated for activity. Median follow-up for overall survival was 7·00 months (IQR 2·96–8·77). Confirmed objective response was achieved in 52 (19·6%, 95% CI 15·0–24·9) of 265 patients. Confirmed objective response was achieved in 23 (28·4%, 95% CI 18·9–39·5) of the 81 patients with PD-L1 expression of 5% or greater, 29 (23·8%, 95% CI 16·5–32·3) of the 122 patients with PD-L1 expression of 1% or greater, and 23 (16·1%, 95% CI 10·5–23·1) of the 143 patients with PD-L1 expression of less than 1%. Grade 3–4 treatment-related adverse events occurred in 48 (18%) of 270 patients—most commonly grade 3 fatigue and diarrhoea, which each occurred in five patients. Three deaths were attributed to treatment (pneumonitis, acute respiratory failure, and cardiovascular failure).

Interpretation

Nivolumab monotherapy provided meaningful clinical benefit, irrespective of PD-L1 expression, and was associated with an acceptable safety profile in previously treated patients with metastatic or surgically unresectable urothelial carcinoma.

Funding

Bristol-Myers Squibb

References checkmate 274 study

REFERENCES

1. Alfred Witjes J, Lebret T, Compérat EM, et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancerEur Urol 2017;71:462–75. [PubMed[]
2. National Comprehensive Cancer Network. Bladder cancer version 6. 2020. (https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf).
3. Rouprêt M, Babjuk M, Burger M, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2020 updateEur Urol 2021;79:62–79. [PubMed[]
4. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patientsJ Clin Oncol 2001;19:666–75. [PubMed[]
5. Birtle A, Johnson M, Chester J, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trialLancet 2020;395:1268–77. [PMC free article] [PubMed[]
6. Dash A, Galsky MD, Vickers AJ, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladderCancer 2006;107:506–13. [PubMed[]
7. Necchi A, Lo Vullo S, Mariani L, et al. Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology-Young Academic Urologists and the Upper Tract Urothelial Carcinoma CollaborationBJU Int 2018;121:252–9. [PubMed[]
8. Xylinas E, Rink M, Margulis V, et al. Impact of renal function on eligibility for chemotherapy and survival in patients who have undergone radical nephro-ureterectomyBJU Int 2013;112:453–61. [PubMed[]
9. Donat SM, Shabsigh A, Savage C, et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experienceEur Urol 2009;55:177–85. [PubMed[]
10. Sternberg CN, Skoneczna I, Kerst JM, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trialLancet Oncol 2015;16:76–86. [PubMed[]
11. Cognetti F, Ruggeri EM, Felici A, et al. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trialAnn Oncol 2012;23:695–700. [PubMed[]
12. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis CollaborationEur Urol 2005;48:189–99. [PubMed[]
13. Sharma P, Callahan MK, Bono P, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trialLancet Oncol 2016;17:1590–8. [PMC free article] [PubMed[]
14. Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trialLancet Oncol 2017;18:312–22. [PubMed[]
15. Sharma P, Siefker-Radtke A, de Braud F, et al. Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort resultsJ Clin Oncol 2019;37:1608–16. [PMC free article] [PubMed[]
16. Opdivo (nivolumab) [package insert]. Princeton, NJ: Bristol Myers Squibb, 2020. []
17. European Medicines Agency. Summary of product characteristics (https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf).
18. Kim HS, Seo HK. Immune checkpoint inhibitors for urothelial carcinomaInvestig Clin Urol 2018;59:285–96. [PMC free article] [PubMed[]
19. Bellmunt J, Hussain M, Gschwend JE, et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trialLancet Oncol 2021;22:525–37. [PMC free article] [PubMed[]
20. Galsky MD, Hahn NM, Rosenberg J, et al. Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapyJ Clin Oncol 2011;29:2432–8. [PubMed[]
21. Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. National Cancer Institute, June 14, 2010. (https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40). []
22. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncologyJ Natl Cancer Inst 1993;85:365–76. [PubMed[]
23. EuroQol Group. EuroQol — a new facility for the measurement of health-related quality of lifeHealth Policy 1990;16:199–208. [PubMed[]
24. Lan GKK, Demets DL. Discrete sequential boundaries for clinical trialsBiometrika 1983;70:659–63. []
25. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinomaN Engl J Med 2015;373:1803–13. [PMC free article] [PubMed[]
26. Pradère B, Thibault C, Vetterlein MW, et al. Peri-operative chemotherapy for muscle-invasive bladder cancer: status-quo in 2017Transl Androl Urol 2017;6:1049–59. [PMC free article] [PubMed[]
27. Shariat SF, Karakiewicz PI, Palapattu GS, et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research ConsortiumJ Urol 2006;176:2414–22. [PubMed[]
28. Fajkovic H, Cha EK, Xylinas E, et al. Disease-free survival as a surrogate for overall survival in upper tract urothelial carcinomaWorld J Urol 2013;31:5–11. [PubMed[]
29. Sonpavde G, Khan MM, Lerner SP, et al. Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancerJ Urol 2011;185:456–61. [PubMed[]
30. Kim HS, Jeong CW, Kwak C, Kim HH, Ku JH. Disease-free survival at 2 and 3 years is a significant early surrogate marker predicting the 5-year overall survival in patients treated with radical cystectomy for urothelial carcinoma of the bladder: external evaluation and validation in a cohort of Korean patientsFront Oncol 2015;5:246. [PMC free article] [PubMed[]
31. Rink M, Lee DJ, Kent M, et al. Predictors of cancer-specific mortality after disease recurrence following radical cystectomyBJU Int 2013;111:E30–E36. [PubMed[]
32. Rink M, Sjoberg D, Comploj E, et al. Risk of cancer-specific mortality following recurrence after radical nephroureterectomyAnn Surg Oncol 2012;19:4337–44. [PMC free article] [PubMed[]

Plaats een reactie ...

Reageer op "Immuuntherapie met nivolumab geeft uitstekende resultaten bij gevorderde uitgezaaide blaaskanker - urineleiderkanker"


Gerelateerde artikelen
 

Gerelateerde artikelen

Atezolizumab als eerstelijnstherapie >> Atezolizumab, een anti-PD >> nivolumab plus gemcitabine >> Immuuntherapie met Tislelizumab >> C-reactief proteïne bloedwaarden >> Immuuntherapie met maandelijkse >> Immuuntherapie met nivolumab >> Circulerend tumor-DNA voorspelt >> Hoe eerder na chemo gestart >> Immuuntherapie met gemoduleerd >>